- Crinetics Pharmaceuticals (CRNX, Financial) will present eight abstracts at ENDO 2025, showcasing data on its endocrinology pipeline.
- Key highlights include long-term efficacy and safety data for PALSONIFYâ„¢ (paltusotine) in acromegaly and Phase 2 trial results for atumelnant in congenital adrenal hyperplasia (CAH).
- Presentations will also feature data from the early-stage program for Graves' hyperthyroidism, broadening Crinetics' focus on significant unmet needs in endocrine disorders.
Crinetics Pharmaceuticals (CRNX) is set to present eight abstracts from its clinical development programs at the Endocrine Society's Annual Meeting, ENDO 2025, scheduled for July 12-15, in San Francisco. This significant presentation will highlight the company's robust endocrinology pipeline, including advanced data from multiple drug candidates.
The prime focus will be on PALSONIFYâ„¢ (paltusotine), a once-daily oral investigational treatment for acromegaly. Crinetics will unveil long-term efficacy and safety data from the PATHFNDR trials, which demonstrate consistent biochemical and symptom control in patients transitioning from injectable somatostatin receptor ligands (SRLs) to the oral formulation.
Another key presentation centers on atumelnant, for which Phase 2 trial results in congenital adrenal hyperplasia (CAH) will be showcased. The data suggest promising biological activity, featuring reductions in adrenal volume and sustained decreases in 11-oxygenated androgens.
Additionally, Crinetics will introduce preliminary data from its early-stage research on CRN12755, targeting Graves' hyperthyroidism and orbitopathy. This expansion into another endocrine disorder could address further unmet clinical needs.
Crinetics is also hosting two sponsored science and innovation theaters at ENDO 2025, focusing on improving long-term management and patient outcomes for acromegaly. These presentations underscore Crinetics’ strategic focus on rare endocrine disorders, aiming to establish leadership in the endocrine therapeutics market.
